Memorial Sloan Kettering Cancer Center (MSK) is one of the worlds premier cancer centers, committed to exceptional patient care, leading-edge research, and superb educational programs. The institution is a comprehensive cancer center whose purposes are the treatment and control of cancer, the advancement of biomedical knowledge through laboratory and clinical research, and the training of scientists, physicians and other health care workers.
The Levine lab is seeking a highly motivated and successful individual with a background in biology, genomics and prior experience or interest in bioinformatics. The lab focuses on investigating how genomic alterations give rise to hematologic malignancies. This includes investigation of mechanisms that drive disease initiation, progression, and response to therapy, at the gene and pathway level. As well, we have a focus on pre-clinical investigation of novel therapeutic approaches that have potential for translation into the clinic.
Our group is highly collaborative, both within MSK and outside. The candidate will become part of a diverse and multi-disciplinary team of students, postdocs and research technicians in our research group.
Investigation of mechanisms of TP53 mutant leukemogenesis.
Evaluation of biomarkers of therapeutic response in Myeloproliferative Neoplasms (MPNs).
Investigation of mechanisms of disease progression in MPNs.
Pre-clinical investigation of Novel mechanism-based therapeutic strategies in myeloid malignancies.
The ideal candidate should have:
A Ph.D. or M.D./Ph.D. in genetics, molecular biology, cancer biology, or related field.
Training in bioinformatics
Excellent oral and written communication skills
Collaborative skills and the ability to work in a team
Ability to perform self-directed and guided research
Please send CV, a letter outlining your interest and names/contact information of three references via email to:
As one of the world's premier cancer centers, Memorial Sloan-Kettering Cancer Center is committed to exceptional patient care, leading-edge research, and superb educational programs. The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available today as we work to discover more effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and the biomedical research agenda around the world.